MODERN APPROACHES TO DIAGNOSTICS AND MANAGEMENT OF CARDIOVASCULAR PATHOLOGY IN PREGNANT WOMEN: FROM INNOVATIONS TO CLINICAL REALITIES OF UZBEKISTAN
Vol. 5 No. 6 Part 2 (2025): Eurasian Journal of Medical and Natural Sciences 43-49
Abstract
Cardiovascular diseases (CVD) are the leading cause of maternal mortality. Pregnancy creates a unique hemodynamic load, decompensating existing or provoking new pathologies (for example, peripartum cardiomyopathy). Modern management is based on innovative diagnostics (3D echocardiography, speckle-tracking, cardioMRI, new biomarkers), preconception counseling using risk stratification (mWHO) and the work of multidisciplinary teams. The key benchmarks are current guidelines (ESC 2023, AHA / ACC, WHO, RCOG). Over the past 5 years, Uzbekistan has developed a specialized clinical protocol for the management of pregnant women with CVD, adapted to national realities and based on international standards, which is an important step in reducing maternal mortality.
Keywords:
References
Regitz-Zagrosek V, et al. 2023 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2023; ehad655. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad655/7330755
WHO. Maternal mortality. Fact sheet, 2023. https://www.who.int/news-room/fact-sheets/detail/maternal-mortality
Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014; 130(12):1003-8. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.009029
Bauersachs J, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(7):827-843. https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1493
Roos-Hesselink JW, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. 2013;34(9):657-65. https://academic.oup.com/eurheartj/article/34/9/657/455400
Donal E, et al. Speckle tracking echocardiography: a new technique for assessing myocardial function. J Mal Vasc. 2011;36(5):336-41. https://pubmed.ncbi.nlm.nih.gov/21802227/
Farsalinos KE, et al. Assessment of left ventricular function by three-dimensional speckle-tracking echocardiography in peripartum cardiomyopathy. Circ Cardiovasc Imaging. 2015;8(5):e002872. https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.114.002872
Donofrio MT, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183-242. https://www.ahajournals.org/doi/10.1161/01.cir.0000437597.44550.5d
Haghikia A, et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090-7. https://academic.oup.com/eurheartj/article/36/18/1090/2293334
Zeisler H, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22. https://www.nejm.org/doi/10.1056/NEJMoa1414838
Greiser A, et al. Cardiovascular magnetic resonance in pregnancy: insights from the German Registry for Pregnancy and Heart Disease (ROPAC). Eur Heart J Cardiovasc Imaging. 2020;21(1):112-120. https://academic.oup.com/ehjcimaging/article/21/1/112/5531221
Valente AM, et al. Multimodality Imaging Guidelines for Patients with Repaired Tetralogy of Fallot: A Report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014;27(2):111-41. https://www.onlinejase.com/article/S0894-7317(13)00885-6/fulltext
Pieper PG, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-97. https://academic.oup.com/eurheartj/article/32/24/3147/469434
Silversides CK, et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol. 2018;71(21):2419-2430. https://www.jacc.org/doi/10.1016/j.jacc.2018.02.076
EMA. Use of medicines during pregnancy. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-topics/use-medicines-during-pregnancy
Stout KK, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Circulation. 2019;139(14):e698-e800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603
WHO. WHO recommendation on the use of low-dose acetylsalicylic acid for the prevention of pre-eclampsia. 2021. https://www.who.int/publications/i/item/9789240035720
Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000923 (Секция по беременности актуальна)
WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011 https://www.who.int/publications/i/item/9789241548335
RCOG. Green-top Guideline No. 13: Cardiac Disease and Pregnancy. 2023 https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/cardiac-diseases-and-pregnancy-green-top-guideline-no-13/
RCOG. Green-top Guideline No. 37a: Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. 2015. https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/reducing-the-risk-of-thrombosis-and-embolism-during-pregnancy-and-the-puerperium-green-top-guideline-no-37a/
Хомидова Ш. М. Уровень антимюллерова гормона у женщин с преждевременным истощением яичников //Достижения науки и образования. – 2020. – №. 3 (57). – С. 104-107.
Хомидова Ш. М. РЕПРОДУКТИВНОЕ ЗДОРОВЬЕ: КЛЮЧЕВЫЕ АСПЕКТЫ ДЛЯ ЖЕНЩИН //Eurasian Journal of Medical and Natural Sciences. – 2024. – Т. 4. – №. 7. – С. 30-33.
Тоджиева Н. И. ПРИМЕНЕНИЕ ФОЛИЕВОЙ КИСЛОТЫ ПРИ БЕРЕМЕННОСТИ: ПРАВИЛЬНАЯ ДОЗА ЗАЛОГ УСПЕХА //Eurasian Journal of Medical and Natural Sciences. – 2024. – Т. 4. – №. 5-1. – С. 142-146.
Published
Issue
Section
How to Cite
